RESUMO
Objective To investigate the efficacy of Taiji quan for cancer related fatigue in advanced lung cancer patients with chemotherapy of paclitaxel combined with cisplatin,and its influence on cellular immune function. Methods From June 2016 to December 2017,78 patients with advanced lung cancer in Zhuji Hospital of Traditional Chinese Medicine were selected and randomly divided into observation group and control group by random number table method,with 39 cases in each group. The control group was treated with TP chemotherapy regimens. On the basis of the control group,the observation group was given Taiji quan. Both two groups were observed for 6 weeks. The scores of cancer related fatigue PFS scale,life quality FACT－G scale and short－term curative effect were compared between the two groups. The cellular immune function T －lymphocyte subsets CD+3, CD+3/CD+4, CD+3/CD+8were detected in the two groups. Results The scores of cancer related fatigue(emotion,feeling,behavior,cognition) of the observation group were obviously lower than those of the control group( t=7. 797,12. 385,9. 386,10. 270,all P=0. 000). After treatment,the scores of life quality FACT－G scale(physiological condition,emotional state,society/family state,function state) of the observation group were remarkably higher than those of the control group(t =6. 764, 6. 218,7. 945,8. 026,all P=0. 000). The short－term effective rate of the observation group was 51. 28% (20/39), which was higher than 25. 64% (10/39) of the control group(χ2=4. 388,P=0. 036). After treatment,the levels of CD+3,CD+3/CD+4of the observation group were obviously higher than those of the control group,while the level of CD+3/CD+8was lower than that of the control group,the differences were statistically significant(t=9. 183,9. 327, 4. 848,all P=0. 000). Conclusion Taiji quan can improve cancer related fatigue and life quality,increase short－term curative effect,and can enhance cellular immune function after chemotherapy of paclitaxel combined with cisplatin.
RESUMO
Objective To evaluate the effect of oxaliplatin induced autophagy on drug resistance of gastric cancer cells. Methods Gastric cancer SGC7901 cells were cultured in vitro and treated with different concentrations of oxaliplatin. Control group (oxaliplatin 0 μmol/ L),oxaliplatin treatment groups (oxaliplatin 1,2,4 μmol/ L)and oxaliplatin combined with doxorubicin groups (oxaliplatin 0,1,2,4 μmol/ L + doxoru-bicin 4 μmol/ L)were set up. Cells were treated with different conditions for 24 hours. Western blotting and flow cytometry were used to detect the expression of autophagy-related molecule Beclin-1. Methyl thiazolyl tetrazolium (MTT)assay was used to detect the cell viability. Flow cytometry was used to analyze the uptake of doxorubicin in SGC7901 cells. Results The expression of Beclin-1 increased in gastric cancer cells treated with oxaliplatin. The percentages of positive cells treated with 1,2 and 4 μmol/ L oxaliplatin were respectively (9. 51 ± 0. 27)％,(13. 73 ± 0. 80)％ and (20. 17 ± 1. 03)％,control group was (2. 17 ± 0. 15)％,and the difference was statistically significant (F = 111. 10,P < 0. 001). Compared with the control group,Beclin-1 expression significantly increased in each treatment group (P < 0. 05;P < 0. 001;P < 0. 001). Different con-centrations of 1,2,4 μmol/ L oxaliplatin combined with doxorubicin were used to treat gastric cancer SGC7901 cells,fluorescence intensities of doxorubicin were 11567 ± 802,13433 ± 808,15967 ± 472,control group was 10257 ± 367,and the difference was statistically significant (F = 79. 81,P < 0. 001). Compared with the control group,the fluorescence intensity of doxorubicin significantly increased in each treatment group (P <0. 05;P < 0. 001;P < 0. 001 ). After treatment with oxaliplatin (1,2,4 μmol/ L)and doxorubicin (4 μmol/ L)for 24 hours,the cell viability levels were (68. 27 ± 1. 64)％,(51. 72 ± 1. 93)％,(39. 60 ± 1. 80)％ respectively. The cell viability levels of oxaliplatin treated with 1,2 and 4 μmol/ L were respectively (93. 70 ± 1. 15)％,(76. 53 ± 1. 10)％,(74. 00 ± 1. 65)％ . Compared with oxaliplatin alone,oxaliplatin combined with doxorubicin decreased cell viability more obviously,and the differences were statistically signifi-cant (t = 8. 91,P < 0. 001;t = 9. 21,P < 0. 001;t = 10. 34,P < 0. 001). The doxorubicin fluorescence inten-sity of oxaliplatin (2 μmol/ L)combined with doxorubicin (4 μmol/ L)group with pretreatment of autophagy inhibitor was 16898 ± 105,oxaliplatin combined with doxorubicin group was 22245 ± 168,and doxorubicin alone group was 17562 ± 67,and the difference was statistically significant (F = 92. 16,P < 0. 001). Com-pared with the pretreatment group,the doxorubicin fluorescence intensity of oxaliplatin combined with doxorubi-cin group was significantly increased (P < 0. 001). On the other hand,the cell viability levels of the above three groups were (81. 33 ± 3. 54)％,(65. 00 ± 2. 61)％ and (101. 02 ± 3. 58)％,and the difference was statistically significant (F = 90. 66,P < 0. 001). Compared with the pretreatment group,the cell viability level of oxaliplatin combined with doxorubicin group was significantly lower (P < 0. 001). Conclusion Oxaliplatin can reduce the resistance of gastric cancer cells to chemotherapeutics by increasing the level of autophagy in gastric cancer cells,and improve the therapeutic effect of chemotherapy drugs.
RESUMO
Objective:To investigate and compare the effects of oxaliplatin combined with gemcitabine administered in a fixed dose rate and that administered in a more standard infusion in advanced biliary tract cancer patients on chemotherapeutic efficacy, toxicities, and survival time. Methods:A total of 93 cancer patients were recruited from February 1, 2010 to December 12, 2012 in the First Hospital of Huai'an City Affiliated Nanjing Medical College. Those recruited were either newly diagnosed unresectable advanced biliary tract cancer patients by percutaneous liver biopsy or relapse or metastatic biliary tract cancer patients after operation. The patients were randomly divided into two groups. The first group was the study group in which the patients received chemotherapy with gemcitabine in a fixed dose rate of 10 mg/m2 per minute combined with oxaliplatin regimens. The other group was the control group in which the patients received chemotherapy with gemcitabine in a more standardized infusion within 30 min combined with oxaliplatin regimens. Each patient received four cycles, with at least two cycles of chemotherapy with GEMOX regimens every 21 d, with follow-up until death. The chemotherapeutic efficacy was evaluated. Toxicities were documented after each cycle. Results:The clinical characteristics of the two groups were well balanced before chemotherapy (P>0.05). The response rate (RR) and clinical benefit response of the study group were higher than those of the control group (P0.05). Conclusion:Gemcitabine in a fixed dose rate combined with oxaliplatin regimens is a feasible and effective scheme in treating advanced biliary tract cancer patients. RR is higher and OS and TTP are longer under this scheme. Non-hematological toxicities are also well tolerated. However, hematological toxicity is distinguished. These results guide us to be prudent in utilizing this regimen. The investigation of the value of gemcitabine in a fixed dose rate combined with oxaliplatin in treating advanced biliary tract cancer patients is worth pursuing in future clinical trials.
RESUMO
The efficacy and safety of the recombinant mutant human tumor necrosis factor (rmhTNF) combined with chemotherapy vs chemotherapy alone in the treatment of patients with small cell lung cancer (SCLC) were evaluated in this study. The selected 37 patients with SCLC were divided into experimental group (n = 18) and control group (n = 19). Bothgroups were subjected to EP regimen. While in the experimental group, a regimen of 4 × 106 U/m2 rmhTNF intramuscular injection was given once a day from the 1st to 7th day and 11th to 17th day on the chemotherapy cycle.Twenty-one days were as a chemotherapy cycle and all patients received treatment with 2 cycles.The response rate was 83.3 % (15/18) in the experimental group and 63.2 % (12/19) in the control group respectively (P＜0.05). The KPS score after treatment was 78.4±9.6 in the experimental group and 71.2±9.7 in the control group with the difference being significant (P＜0.05).No severe adverse effects occurred in the two groups. It was concluded that the curative effectiveness of the rmhTNF combined with chemotherapy in the treatment of SCLC was more satisfactory than chemotherapy alone. The former could obviously improve the quality of life of the patients with SCLC.